Cleave names new VP, clinical development
This article was originally published in Scrip
Executive Summary
Cleave Biosciences has named Dr Kanya Rajangam vice-president of clinical development. Dr Rajangam will lead Cleave's ongoing clinical trials and design future studies to evaluate drug candidate CB-5083 in hematological and solid tumor malignancies, as well as advance other internally discovered compounds into development. Most recently she was executive director of the oncology and immuno-oncology program at Nektar Therapeutics. Cleave also announced that chief medical officer Dr Alessandra Cesano is leaving the company to pursue other opportunities.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.